Cyclacel Pharmaceuticals Inc
CYCC
Market Cap$95.76M
Close$
$0.60
100.6% upside
Current Fair Value
100.6% upsideUndervalued by 100.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $95.76 Million |
|---|---|
| Enterprise Value | $92.62 Million |
| Dividend Yield | $0.15 (59.7133757961783%) |
| Earnings per Share | $-5.21 |
| Beta | 0.16 |
| Outstanding Shares | 2,152,202 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.06 |
|---|---|
| PEG | 0.06 |
| Price to Sales | - |
| Price to Book Ratio | -0.15 |
| Enterprise Value to Revenue | 1543.32 |
| Enterprise Value to EBIT | -7.1 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Cyclacel Pharmaceuticals Inc
2,018 employees
CEO: Spiro Rombotis Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in cell cycle, transcriptional regulation and DNA damage response biology in cancer cells to develop innovative medicines. The transcriptional reg...